Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.72 |
| ▸ | EGFR | P00533 | 8/20 | 0.72 |
| ▸ | FLT4 | P35916 | 5/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.72 |
| ▸ | FLT1 | P17948 | 3/20 | 0.72 |
| ▸ | SRC | P12931 | 9/20 | 0.68 |
| ▸ | AURKA | O14965 | 3/20 | 0.63 |
| ▸ | TEK | Q02763 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | KIF5B | P33176 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203336 | 0.90 | KDR (0.84) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL7573245 | 0.89 | KDR (0.83) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL3185479 | 0.87 | EGFR (0.75) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL27218174 | 0.83 | EGFR (1.00) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL5218947 | 0.83 | SRC (0.87) | KDREGFRFLT4FGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL30891785 | 0.81 | EGFR (0.84) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL3208481 | 0.80 | SRC (0.86) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL7867152 | 0.80 | KDR (0.98) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL7864675 | 0.80 | KDR (0.90) | KDREGFRFLT4FGFR1FLT1 | |
| SCHEMBL3679436 | 0.79 | KDR (0.88) | KDREGFRFLT4FGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004087120-A2 | USE OF QUINAZOLINE DERIVATIVES WITH SRC KINASE INHIBITORY ACTIVITY FOR THE TREATMENT OF HYPERTENSION | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | KDR 5/4885EGFR 124/4885FLT4 3/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | KDR 825/4885EGFR 155/4885FLT4 568/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | KDR 10/4885EGFR 233/4885FLT4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.